FAM71E2

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, FAM71E2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM71E2 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher FAM71E2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM71E2 expression acts as an unfavorable survival marker.

ACC, UCEC, and COAD are the cancer types where FAM71E2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
ACCDFSMedianAll0.0460.753<.00136view →
UCECOSMedianIV0.2310.592.0366view →
COADOSMedianII,III,IV0.1680.788.0056view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FAM71E2–ACC (DFS)

Kaplan–Meier survival curve for FAM71E2 mutant vs wild-type samples in ACC.

Open the ACC breakdown →

Exploration